Opdivo

Latest trial win further supports expanded use of Bristol Myers’ Opdivo in lung cancer
Latest trial win further supports expanded use of Bristol Myers’ Opdivo in lung cancer
BioPharma Dive
Bristol Myers Squibb
Opdivo
non-small cell lung cancer
clinical trials
Flag link:
Bristol Myers gets positive opinion from CHMP for Opdivo
Bristol Myers gets positive opinion from CHMP for Opdivo
Pharmaceutical Business Review
Bristol Myers Squibb
Opdivo
CHMP
Europe
melanoma
Flag link:
Bristol Myers' Opdivo stages comeback in bladder cancer, teeing up 2 'Merck' showdowns
Bristol Myers' Opdivo stages comeback in bladder cancer, teeing up 2 'Merck' showdowns
Fierce Pharma
Bristol Myers Squibb
Opdivo
bladder cancer
Merck
Flag link:
Sellas celebrates positive Phase I results in lung cancer
Sellas celebrates positive Phase I results in lung cancer
Clinical Trials Arena
Sellas
clinical trials
immunotherapy
Opdivo
mesothelioma
lung cancer
Flag link:
ASCO: Seagen's top-selling drug under threat as Bristol Myers' Opdivo beats Adcetris in lymphoma
ASCO: Seagen's top-selling drug under threat as Bristol Myers' Opdivo beats Adcetris in lymphoma
Fierce Pharma
ASCO 2023 - Seagen
Bristol Myers Squibb
Adcetris
Opdivo
antibody-drug conjugate
Hodgkin's lymphoma
Flag link:
Bristol Myers accuses AstraZeneca of infringing patent on cancer blockbuster Opdivo—again
Bristol Myers accuses AstraZeneca of infringing patent on cancer blockbuster Opdivo—again
Fierce Pharma
Bristol Myers Squibb
Opdivo
patents
legal
AstraZeneca
Flag link:
Most-clicked pharma news for week ending March 18 2023: Medtronic offers early retirement package, Novartis to sell ophthalmological assets, and Pfizer tops list of drugs with price increases
Most-clicked pharma news for week ending March 18 2023: Medtronic offers early retirement package, Novartis to sell ophthalmological assets, and Pfizer tops list of drugs with price increases
CP WIre
Medtronic
Medtech
inflation
drug pricing
Pfizer
Novartis
Merck
Bristol Myers Squibb
Keytruda
Opdivo
Yervoy
lung cancer
Xiidra
JNJ
executive compensation
Flag link:
Most-clicked pharma news for week ending March 18 2023: Medtronic offers early retirement package, Novartis to sell ophthalmological assets, and Pfizer tops list of drugs with price increases
Medtronic
Medtech
inflation
drug pricing
Pfizer
Novartis
Merck
Bristol Myers Squibb
Keytruda
Opdivo
Yervoy
lung cancer
Xiidra
JNJ
executive compensation
Flag link:
In PD-1 rivalry, Merck's Keytruda catches up with Opdivo in rare lung cancer type
In PD-1 rivalry, Merck's Keytruda catches up with Opdivo in rare lung cancer type
Fierce Pharma
Merck
Keytruda
Opdivo
Bristol Myers Squibb
pleural mseothelioma
mesothelioma
clinical trials
Flag link:
Bristol Myers axes German launch of new cancer drug, citing pricing hurdles
Bristol Myers axes German launch of new cancer drug, citing pricing hurdles
Endpoints
Bristol Myers Squibb
Germany
Opdivo
Opdualag
Flag link:
Big pharma’s looming threat: a patent cliff of ‘tectonic magnitude’
Big pharma’s looming threat: a patent cliff of ‘tectonic magnitude’
BioPharma Dive
Big Pharma
patents
patent cliff
biosimilars
AbbVie
Humira
Merck
Keytruda
Bristol Myers Squibb
Opdivo
Flag link:
Compugen COM701 in dual/triple combo shows promise in ovarian cancer patients in trial
Compugen COM701 in dual/triple combo shows promise in ovarian cancer patients in trial
Seeking Alpha
CompuGen
COM701
Bristol Myers Squibb
Opdivo
ovarian cancer
platinum-resistant ovarian cancer
Flag link:
Bristol Myers spells out Opdivo win in melanoma — how does it stack up against Keytruda?
Bristol Myers spells out Opdivo win in melanoma — how does it stack up against Keytruda?
Endpoints
Bristol Myers Squibb
Opdivo
melanoma
Merck
Keytruda
Flag link:
Bristol Myers' Opdivo win tees up showdown with Keytruda in earlier-stage melanoma
Bristol Myers' Opdivo win tees up showdown with Keytruda in earlier-stage melanoma
Fierce Pharma
Merck
Keytruda
Bristol Myers Squibb
Opdivo
melanoma
Flag link:
ESMO: Bristol Myers, Roche fail in post-surgery kidney cancer. But is it good news for Merck's Keytruda?
ESMO: Bristol Myers, Roche fail in post-surgery kidney cancer. But is it good news for Merck's Keytruda?
Fierce Pharma
ESMO
Roche
Bristol Myers Squibb
kidney cancer
Keytruda
Merck
Opdivo
Yervoy
Flag link:
Exelixis trot out Opdivo-Yervoy-Cabometyx combo win in kidney cancer. Will FDA accept?
Exelixis trot out Opdivo-Yervoy-Cabometyx combo win in kidney cancer. Will FDA accept?
Fierce Pharma
Exelixis
Cabometyx
kidney cancer
Opdivo
Yervoy
Bristol Myers Squibb
Flag link:
ASCO: Bristol Myers adds to debate with Opdivo's presurgery lung cancer performance
ASCO: Bristol Myers adds to debate with Opdivo's presurgery lung cancer performance
Fierce Pharma
ASCO 2022
Bristol Myers Squibb
lung cancer
Opdivo
Flag link:
The patent winter is coming
The patent winter is coming
EP Vantage
patents
biosimilars
patent cliff
Keytruda
Opdivo
Eliquis
Darzalex
Revlimid
Humira
Stelara
AbbVie
Merck
Bristol Myers Squibb
JNJ
Flag link:
Bristol needs to get fresh
Bristol needs to get fresh
EP Vantage
Bristol Myers Squibb
Opdivo
Flag link:
Bristol Myers scraps $2B Nektar partnership after trial failures
Bristol Myers scraps $2B Nektar partnership after trial failures
BioPharma Dive
Bristol Myers Squibb
Nektar Therapeutics
immunotherapy
Opdivo
kidney cancer
bladder cancer
Flag link:

Pages